current position：Home>Reflections on the fourth anniversary of Hong Kong stock 18a
Reflections on the fourth anniversary of Hong Kong stock 18a
2022-05-07 14:52:02【100 million euros】
Titanium media injection ： This article is from the official account of WeChat Yiou is talkative （ID：EO-Healthcare）, author | Green lacquer leaves , edit | Liu Cong , Authorized release of titanium media .
Final , In less than C The issue price of the round financing cost ——7.13 The Hong Kong dollar / stocks , Lepu biology, which submitted its prospectus twice, is in 2 month 23 Complete the listing and trading on the th , After breaking the market of Sano Pharmaceutical 、 Hong Kong 18A Two months of silence , It also becomes the help of 18A Policy success IPO Of the 49 Unprofitable biotech companies .
The debut after listing is not too bad , After all, it's better than breaking all the way on the first day of listing “ predecessors ” People ,7.14 The closing price of Hong Kong dollar 、 Slight inflation 0.14% The result is pretty good . But LEP biology hasn't maintained this momentum for long , The next day it fell below the issue price , Since then, the stock price has been 6.5 The Hong Kong dollar hovers —— And this has become almost all 18A The epitome of the company .
18A policy , Derived from 2017 end of the year , HKEx opens 24 The biggest reform of the listing system in recent years . The following year 4 month , new 《 Listing rules 》 In force ,“ No income is allowed 、 Unprofitable biotechnology companies submit listing applications ” Of the 18A Chapter becomes the biggest attraction .
At the time , As the scientific innovation board has not been opened yet , A company without profit will never land A The possibility of the stock market , U.S. stocks on the other side of the Pacific as the only option , Also because of the differences between cultural habits and market cognition , Not for all Chinese companies .
thus , Hong Kong 18A Once launched, it has become the first choice for many unprofitable biotechnology companies to go public , The HKEx has also repeatedly said , “ We have confidence in , Hong Kong will become one of the most important medical and biotechnology centers in the world ”.
The truth seemed like this for a time , In especial 2020 Driven by the COVID-19 , The biomedical sector has become an absolute C position , Baiji Shenzhou 、 A number of star pharmaceutical stocks such as Cinda biology have been on the stage one after another ,18A The company has earned enough market attention .
Then , On the fourth anniversary of this policy , The boundless strongest winter came across unexpectedly . The superimposed impact of various macro factors , Coupled with the structural problems faced by the pharmaceutical sector itself , A the 18A The company cast a shadow , Ninety percent of enterprises have fallen below the issue price , Enterprises still waiting in line can only wait , Or bite your teeth and go on sale like the LEP creature at the beginning .
Under the changing situation ,18A Does the company still have the value of investment , How much benefit can innovative medicine and equipment bring , Can it even bring benefits , It has become a hot topic and the biggest worry between investors and business leaders .
01、 from 0 To 1 Exploration
2018 year 4 month 30 Japan , The first 18A Chapter listing rules come into force , achieve “ At least one core product has passed the concept stage ”“ The expected market value is no less than 15 Million Hong Kong dollars ” Upon request , Relevant biotechnology companies are qualified for listing . Add... After the stock abbreviation of such listed companies “B”, To remind investors of risks .
At the time , With China's new drug approval system 、 Reform of the medical insurance system , And the return of a large number of overseas talents , China's innovative drug industry is developing rapidly .18A The launch of the Listing Rules coincides with the time , It opened the door of capital market for innovative drug enterprises in time , It also set off an investment boom in the secondary market .
Meng Yi, general manager and vice chairman of HSBC Global Bank in China, is a metaphor ,18A The introduction of the policy is like a catalyst , For the development of innovative medicine and equipment, it is known as “10 Annual grinding sword ” Tough track , Inserted into the wind and fire wheel of capital , Solved a problem from 0 To 1、 A problem from scratch .
Self singing ritual medicine has become the first enterprise to eat crabs , For the past four years , share 50 A biotechnology company is based on 18A The rules of relevant chapters are listed in Hong Kong , The total raised funds exceed 1100 Million Hong Kong dollars .
among ,2018 year 、2019 year 、2020 year 、2021 year ,18A The listed companies are 5 home 、9 home 、14 home 、20 home , Showing a steady trend of listing year by year .
And the annual raised funds reached 185 Billion 、161 Billion 、404 Billion 、377 Million Hong Kong dollars , among ,2018 year 8 month 8 Baiji Shenzhou, which went public on the th, can be called “ The fundraiser ”,70.85 The fund-raising amount of HK $billion “ Ride a dust storm ”, The minimum raised capital is 4.79 Million Hong Kong dollars , by 2019 year 10 month 28 Yasheng medicine, which went on sale on the th .
Look at the track , this 50 Home company , Pharmaceutical enterprises have a total of 37 home , Of the total 74%, Covering tumors 、 Autoimmune diseases 、 Ophthalmology Department 、 The vaccine 、 Cell therapy 、 diabetes 、 Infectious Diseases 、 Respiratory diseases and rare diseases 9 Large area ; Medical device companies have 13 home , Occupy 26%, Focus on vascular intervention 、 Neurosurgery 、 Molecular diagnostics 、 Diagnosis and treatment equipment, etc .
According to the regulation , The annual income is more than 5 Million Hong Kong dollars , The market value is greater than 40 A company with a condition of HK $100 million , May be removed with the approval of the stock exchange “B” Mark , That is, it is equivalent to listing on the main board of the stock exchange under the general rules . at present , Baiji Shenzhou 、 Xinda biology 、 Real creatures 、 Fuhong Hanlin 4 The company has removed “B” Mark .
Besides , It is worth mentioning that , actually , stay 18A One year after the policy was launched , The fifth set of listing standards of domestic science and technology innovation board also began to release unprofitable biotechnology companies . by comparison , Although the Hong Kong stock market is relatively weak A Shares are undervalued , But more mature and stable , Connect with international mainstream institutional investors , Refinancing has obvious advantages , And the lifting rules after listing are more relaxed .
For the specific selection and comparison of dual listing , Fuhong Hanlin CFO Li Xinlei once said at a live broadcast that , The regulatory environment and regulatory requirements on both sides have their own characteristics , In terms of refinancing speed, Hong Kong stocks have more advantages , But from a valuation perspective A Shares have more advantages , Therefore, we should combine the business characteristics of the enterprise 、 Shareholder structure 、 Future strategic development requires an overall consideration of this matter .
Where to go public may be more a matter for enterprises to choose , However, the adjustment and change of the detailed rules of the science and innovation board itself is of great significance to 18A There will be a force . A typical such as 2021 Beginning of the year , The wind that the audit of science and innovation board is becoming stricter 、 And the scientific innovation board “ Standard five ” The of innovative medical device enterprises is noncommittal , It further triggered almost all innovative medical device enterprises to list in Hong Kong as their first choice , It also forms 2021 Hong Kong stock market 18A A wave crest of the number of listed medical device enterprises .
02、18A When the company wakes up
In a sense , Hong Kong 18A The policy overturned the past investment strategy of capital market on biotechnology companies , While releasing market liquidity in advance , Put the biotechnology investment with high professional threshold in front of the open market and stand the test of the market . As four years passed , More and more companies are accommodated ,18A The market is also experiencing “ Exploration period - Frenzy - Adjustment period ” The stage change of .
Three or four years ago , A group of new drug R & D companies with two or three clinical I The pipeline that hasn't been completed in the period , And a few BD The incoming pipeline runs to the Hong Kong Stock Exchange , The market value of the issue is often doubled , Subscription is also very popular .
2020 In the year , Including kangfang Biology 、 Yongtai Biology 、 Develop the pharmaceutical industry 、 Jiahe Biology 14 An unprofitable biotechnology company is listed on the Hong Kong stock exchange , The average increase of these companies on the first day of listing is about 26%, The average cumulative increase in the whole year reached 36.1%. To 2021 Nuohui health, which was listed on the first trading day after the Spring Festival in , More directly created 18A The first day of the company's listing was the highest .
Now , This lively situation has dissipated , Whether in terms of the number of listed companies or the year-on-year performance of stock prices, it is not satisfactory .
2022 The first four months of the year are almost over , This year's 18A The company only uses Lepu Biology 、 Reco biology , No more... Every month before 1、2 The frequency of home . At this release speed , All year round 18A Whether the number of listed companies can reach double digits is a suspense .
And from last year 8 Month begins ,18A New shares have basically fallen into the dilemma of breaking the last one , Including Xinwei Medical 、 Chuangsheng group 、 Kunbo Medical 、 Heyu 、 Hokkaido Kangcheng 、 Clover biology, etc. broke on the first day of listing .
Even scheduled for 11 month 26 This is also the case with baixin'an, which was listed on the 20th ： Due to the lack of cornerstone investors , Unable to complete the fundraising , It had to take the initiative to stop on the eve of listing , Cancellation of sale 、 Delay the offering plan , And return the application share money to the investor .
In the end, Bai Xinan is still 12 month 23 Successfully listed on the 1st , But the situation was once very reluctant , Not only are cornerstone investors still “ leave a blank ”, The issue price is the lower limit of the predetermined range , Subscription multiples are only 1.56 times , Break at the opening , On the first day of listing, when the stock price was the lowest, it was once lower than the issue price 13.78%.
New shares “ Stressed out ”, earlier “ Go ashore ” My company is also having a hard time . according to 4 month 25 Daily closing price calculation ,50 home 18A Nearly 90% of the company has fallen below the issue price , 70% of the company's share price has halved by more than half . One investor said frankly , Some stock prices have fallen to the original B The wheel is even A The valuation of round financing .
Once upon a time License-in The famous zaiding medicine , Now the share price is less than the issue price 1/10, And the first to pass 18A In addition to the first day of listing, the song ritual drugs that landed in Hong Kong stocks , Never exceeded the issue price , Kunbo medical, which belongs to the track of interventional medical devices 、 Serenade Medical 、 Xinwei medical 、 Guichuangtong bridge fell by nearly 80% .
meanwhile , The problem of insufficient liquidity of Hong Kong stocks is also 18A The company is full of . With 4 month 11 Daily data as an example ,23 The turnover of this company is less than 1000 Million Hong Kong dollars , among 9 The turnover of this company is less than 100 Million Hong Kong dollars .
however , It is worth noting that , stay 18A When the company is green , Junshi creatures rely on 169.1% The gains “ stand head and shoulders above others ”, This is mainly its new crown oral medicine VV116 Bring expectations , at present VV116 In the international Multi Center III Phase I clinical research stage . The expectation of the market is ,VV116 If approved successfully , As a help to control the COVID-19 、 One of the options for normalization , Will have great domestic 、 Global market potential .
It's easy to understand that the concept of Xinguan anti epidemic has led to the rise of monarch and real creatures , The sudden counter attack of the once dramatic release of baixinan was more or less unexpected .
Carefully combed and found , The rise of busentan is also driven by the new progress of two products ： One is the second generation Iberis Renal nerve blocking system , The product was first clinically approved in Europe , Then the clinical trial patients were enrolled and the work was completed ; The second is the fist product of baixinan —— Degradable heart stent ,2 month 16 Japan , The product completes the clinical patient enrollment .
03、 Return and proof of value
actually , The secondary market is like an arena , Listed companies are among them PK Who can win the favor of investors , As the number of listed companies increases 、 Investors' optional targets become rich , The polarization of stock prices is understandable , However, the situation of continuous and complete general decline is rare .
For this situation , Many investors said , This is the result of the joint action of internal and external factors .
Cao Jian, founder of Shiyu capital, made a specific analysis ： One side , The whole international environment 、 Changes in global liquidity , Many international investors have continuously reduced the allocation of Chinese , Institutions that used to have pricing power in the Hong Kong market are also selling Hong Kong assets , It has a great impact on the overall market ; On the other hand , After the outbreak, the whole medical field had a big foam , And value needs to rely on the success of commercialization to prove , Now part of it is also returning to the normal value curve .
before , Puyin international has issued Research Report tips ： Under the impact of many overseas risks , At present, a rare signal has emerged in Hong Kong stocks , Investors should attach great importance to .
“ among , From a technical point of view , Heng Seng Index 30 For the first time in years 250 The long-term support of the monthly average , And the current high retreat range is close to 2018 year ; And in terms of capital , The current capital outflow rate of Hong Kong stocks is the same as 2008 The financial crisis in was quite , Second only to 1998 The outflow range during the Asian financial crisis in .” The research report specifically wrote .
Perhaps the signal of market loss is as early as 2021 Years have emerged ——2021 When the world's major indexes showed a positive growth trend in , Only the Hang Seng Index, as a barometer of the Hong Kong stock market, fell significantly .
The turbulent market environment and the current complex situation have intensified the transmission pressure on the capital market , meanwhile , We should also consider the particularity of the biotechnology industry itself .
The biotechnology industry has always been known for its high risk , The whole R & D process costs a lot , so to speak , The import and export of capital is threatening the fate of the whole industry . Over the past few years , A number of biotechnology companies have tasted the sweetness in the first wave of listing , Reaped dividends , Also raised expectations , Make the re entrants have the illusion that they can make money while lying down .
A year ago. , A senior investor once reviewed in an interview with yiouda health 2020 Year market , For example, the blood vessel intervention that was very hot at that time 、 Nerve intervention , The valuations of many popular projects rise again and again , Not only higher than their acceptance , It has even far exceeded the upper limit of market space prediction of the whole track .
What bothered him more was , Some biotech companies with no revenue Pre-IPO The round of valuation itself may not be worth the price , But it has a high probability of going public , After listing, the market value is likely to double directly to 80~100 Billion ,“ Whether you vote or not at this time ？ It is a great test for one's own investment values .”
When the price deviates from the value , The accumulation of foam began to suppress risks . And the current situation , It also verifies the investor's judgment ： With the enterprise financing money , When it comes to the secondary market, it slowly begins to divide , When the organization that invested in bad projects didn't make money in the end , The bubble is broken. , Investors pay for lessons .
Cao Jian emphasized ：“ Finally, the key is to return to the product understanding , Are the products you make really different ？ Is there any innovation ？” With more and more products or homogenization 、 Or enter the clinical discovery data is not good , Or has been approved for listing, but far less than expected , The market tends to return to rational thinking more and more .
This trend is not only reflected in Hong Kong stocks 18A The liquidation of the company , The entire Hong Kong stock pharmaceutical sector 、A The biomedical sector is entering the process of valuation rebalancing . data display ,2021 year A Pharmaceutical biological index （ all ） fall 6.14%, Valuations have shrunk 24.4%; The valuation of the pharmaceutical sector in Hong Kong stocks shrank by 41%.
Li kechun, partner of Yuansheng venture capital, also said ,“ Not just Hong Kong stocks 18A The general decline of the company , Including NASDAQ and other stock indexes are falling , This may also be an economic cycle , The degree of internationalization of Hong Kong stocks is still relatively high ”, And in his opinion , Falling is not necessarily a bad thing ,“ Falling is normal , It's also because the past was too crazy , Now it's time to return value , And falling to this level is just a better chance , In the long run , It will still rise ”.
04、 Bet on what kind of future ？
Rising may be inevitable , But the aforementioned senior investors admitted , The strength and duration of the cold of Hong Kong stocks , Is far more than he expected . So , At the moment , Everyone is asking , When will this cycle end ？ When will the biotechnology sector fight back ？
Zhou chaoze, chief analyst of Minsheng securities pharmaceutical industry, once pointed out , The market dominated by foreign capital must be greatly affected by the geopolitical environment , Now we are concerned about several geopolitical factors , It may directly determine the current situation of Hong Kong stocks 、 It is not just the rebound time opportunity of Hong Kong stock biomedicine or Hong Kong stock as a whole .
“ On the one hand, the time when the conflict between Russia and Ukraine ended , Second, the relationship between China and the United States is moving towards , Third, the pharmaceutical industry itself , The biggest attraction of Chinese enterprises in Hong Kong stock biomedicine is internationalization , Whether the path of internationalization can go through .” Specifically speaking .
Geopolitical factors are elusive , And in this unpredictable cold winter , The first question these biotech companies have to answer is how to survive .
Cao Jian said , The response of the secondary market is relatively rapid , But the adjustment of the primary market has just begun , No more effects have been forced . But one visible sign is , Many institutional investment projects are moving forward in the early stage , “ They just want to push some angel wheels 、A、B Round of projects .” a FA According to institutional sources .
Follow this trend , Cao Jian predicted that , Maybe by the fourth quarter of this year 、 Around the beginning of next year , A number of companies will go bankrupt one after another ,“ Some melt into C、D Even listed companies will go bankrupt , Generally speaking, corporate finance 2~3 The money for , The wave of the epidemic has melted money, and now ,Q4 Or may not be able to endure early next year ”.
throughout 2021 Annual financial report , It's profitable 18A There are few companies , Concord creatures 、 Rongchang biology is the only two of them —— The former benefited from the launch of the new coronavirus vaccine , The profit during the year reached 19.07 One hundred million yuan , Turn a loss into a profit ; The latter mainly comes from the global licensing of the core product vidicizumab , To obtain the 2 $100 million down payment .
These two cases of turning losses also represent the current 18A The company's revenue structure ： First, the sales revenue from the listing of their own products , Second, product licensing revenue from partners . If there is neither , Then considering the duration becomes the most important 、 The most practical question , The direct indicator is the cash balance reserve .
And now , Part of the company's ” Surplus food “ It's not enough . Many industry analyses have been based on 18A company 2021 Statistics have been made in the latest annual report of , Yes 8 home biotech The cash is not enough to maintain more than two and a half years of R & D investment , among 4 I can't make it at home 2 R & D investment in .
Archimedes, a senior person in the pharmaceutical industry, believes that , At least it can support 2 R & D expenditure of more than years , To survive the cold winter . It means , This year there are already 4 Hong Kong stocks 18A The company is in danger of running out of cash , At the same time, about 30% Hong Kong 18A The company in 2024 Facing the situation of running out of cash in .
Really wait until then , Cao Jian believes that , Maybe we can refer to 2000 When the Internet Foam Burst in , After all, the logic of biotechnology companies in this round is so similar to that of Internet enterprises at that time , There is no final commercial realization as a support ,“ There are two ways to die , Some companies can't raise money 、 Things can't be sold , On the survival of the fittest, natural death , Some companies may have money , But lost expectations , Will also be forced to death .”
Total outcome , The dead are those uncompetitive companies , Only those who survive can successfully cross the cycle , Especially for companies that really have core competitiveness , This inevitable process of scouring the sand by waves is preparing for its growth .
Reference material ：
- Sullivan Jerry （ Shenzhen ） Cloud Technology Co., Ltd ,《 Hong Kong 18A Biotechnology companies issue investment reports 》
- Boshui online video live broadcast ,《18A Three years after the new rules , Current situation and challenges of biomedical companies 》
- Guoyuan securities ,《 Innovative medicine weekly ： Hong Kong stock innovative pharmaceutical enterprises 2021 Annual report performance inventory 》
- CAIJIAN road ,《 Life and death of innovative pharmaceutical enterprises 》
- Yinhua Fund “ finger ” Point maze 24 period ,《 Minsheng securities Zhou chaoze ： Whether Hong Kong stock biomedicine can fight back ？》
- Ed Securities Futures ,《18A Research Report on biomedical industry stocks 》
- The first finance and economics, ,《 Biotechnology Enterprises “ Overwintering ”： From relying on external financing to accelerating commercialization 》
- Pharmaceutical investment tribe ,《 Hong Kong stocks do not believe in tears ： Heaven left ,18A towards the right 》
- Liu Xiaolan, managing director of CITIC Securities ,《 Innovative drugs and innovative medical devices choose science and technology innovation board or Hong Kong stocks 18A Comparison of listed companies 》
- Wait and see biomedicine ,2021 Hong Kong stock market 18A reflection ( One )： A few happy and a few sad 、2021 Hong Kong stock market 18A reflection ( Two )： NASDAQ biotech Apocalypse
author[100 million euros],Please bring the original link to reprint, thank you.
The sidebar is recommended
- The U.S. Treasury Department announced its commitment to blender IO cryptocurrency money laundering platform imposes sanctions
- The world's largest hydropower station under construction has generated more than 10 billion kwh of electricity this year
- The court asked all ISPs in the United States to block three pirated websites
- Marshall Emberton II experience: 30 hours longer endurance, more environmentally friendly, and more fun
- Giant biological delivery table Hong Kong stocks, "wanghong" skin care products created 87.2% high gross profit margin - IPO express delivery
- Tropos motors launches compact electric truck: focusing on urban freight, which can quickly replace the module trunk
- NFT collective "cooling down", big factories transfer digital fashion
- Lululemon overturned again. When did "Yoga Lv" take off the label of "poor quality"?
- Lululemon was punished for shoddy goods, and its reputation in the Chinese market "fell"
- It's not easy for pelaya to be an Internet celebrity when she "overturned"
guess what you like
The glory and dream of "Chinese McDonald's"
Marketing, stores and supply chain are fully connected, and Gome joins hands with Tencent to create a full retail ecosystem
Meditation in China, when to wait for unicorns valued at more than $2 billion?
In 2022, the "code assembly" global challenge was launched
State Post Office: the number of suspended distribution centers and mail express backlog in China has decreased significantly
Industry chain news said that the shortage of chips has affected the production of chip manufacturing automation equipment
Cadillac lyriq's first pre production vehicle goes offline
The turbulent history of arm China: the fate of a joint venture in the cracks
Disappeared red cannon
Can Musk's idea of neuralink really work by "curing" tinnitus with brain computer interface?
- How to learn from cattle?
- Foreign venture capital news "AVA" has completed a round of financing of US $10 million and is committed to providing real-time audio transcription services
- Married middle-aged employees who "can scold freely" are actually better?
- Pig heart transplant the first person died, pig heart hidden pig virus
- The winter of network integration starts from the lack of business recruitment
- 36 krypton's exclusive "hydrogen aviation technology" won tens of millions of yuan of a-round investment to promote the diversified application of fuel cells
- In the era of the new national standard of milk powder, who is in charge of the ups and downs of Feihe, JUNLEBAO and Mengniu?
- I heard Dumbledore ordered a song "one hundred years of solitude"?
- "Cycling for ten minutes, parking for an hour", why is it difficult to share a bike?
- Li Ning, shuyishaoxiancao and China Post have poured across the border, and the coffee war has kicked off?
- I didn't win all the time
- Exposure of Musk's humble house: only one block from SpaceX starship base, worth about $50000
- It is revealed that the shortage of chips has affected the production of chip manufacturing automation equipment, and the delivery period of equipment has been extended to more than one year
- Employee of Rouyu: all wages owed have been paid
- It is said that Microsoft is promoting the Xbox everywhere project, and the streaming experience of video games is still expected to come within a year
- AI new century problem: the more you earn, the more you lose
- Elemental OS 7 released its code name
- Help start-ups get money from hundreds of VCs, and their ability circle is still expanding
- Bonus newsletter ｜ home office for all employees in Chaoyang District; Baidu's new round of cadre rotation; BYD fell into a negative storm; Apologize to those who "force employees to work overtime on May Day"; Follow up to the workplace event of "making c
- This is the hottest track. This year, it has run a number of 10 billion unicorns
- Is there still a chance for drones?
- The high-level sense of Chinese stars has been destroyed by the English name of sand sculpture
- Why does wechat choose one out of two?
- She started her career
- Apple has officially integrated icloud "manuscript and data" service into icloud cloud disk
- BMW CFO Nicholas Peter: China has become the world's largest new energy vehicle market and will maintain a leading position in the next few years
- Peking University Mathematics "Wei Shen" went on a hot search again and helped six doctors solve the problems that had plagued them for four months
- Yi Jingjie was selected into the list of "specialized, special and new" enterprises in Guizhou Province in 2022
- First batch! Bank of Beijing, China CITIC construction investment and Taikang group completed the EDMM enterprise digital marketing capability evaluation of China Academy of communications and communications
- Lead the country! Jincang of the National People's Congress helped upgrade the information system of a municipal court in the cloud
- Heavy! The joint solution of medical "data island" is coming
- Kirin software, Godson Zhongke and CLP technology jointly launched the national BMC solution
- Dell technology group and snowflake reach cooperation
- SpaceX launches 53 star chain satellites, giving birth to the third one arrow 12 flight rocket
- Wei Shen of Peking University Mathematics helped six doctors solve problems and went on a hot search
- Snap did not disclose how many pixy flight cameras it has manufactured. The first buyers still need to wait patiently
- When "funny girl" becomes a career
- Every punctuation you leave on the Internet constitutes your future resume
- From a monthly salary of 100 yuan to an annual salary of millions, how does the female leader of Haidilao realize the counter attack of life
- Tesla's "brake failure" has an official solution, emphasizing that automatic driving is eight times more reliable than humans